NAD+
Nicotinamide adenine dinucleotide
A ubiquitous coenzyme rather than a peptide. Direct parenteral NAD+ has a thinner evidence base than oral precursor research.
Mechanism
Cellular redox coenzyme and metabolic substrate
Protocol studied in research
Study design shown in plain language. This is not a personal dosing recommendation.
Human evidence is absent, limited or not confirmatory
Anecdotal schedules are excluded because frequency of online repetition does not establish identity, safety, or a clinically meaningful dose.
Community-Reported Research Schedules
Descriptive community patterns are separated from clearly labeled trial-derived reference rows. Neither is personal dosing guidance.
Infusion and subcutaneous schedules should not be treated as equivalent.
| Research context or phase | Amount per administration | Schedule total | Frequency | Timing | Administration | Evidence level |
|---|---|---|---|---|---|---|
| Common subcutaneous range | 50–100 mg | 50–100 mg per administration | Two or three times weekly | Morning or early day | Subcutaneous | Community-reported |
| Common infusion schedule | 250–500 mg | 250–500 mg/session | Intermittent sessions | Clinic-timed | Intravenous | Community-reported |
Important: Repetition in online communities does not establish product identity, safety, effectiveness, or an appropriate exposure. Route-specific schedules, half-life estimates and reported cycle lengths are shown for comparison only.
Example Reconstitution Protocol
A hypothetical concentration calculation for literacy and review—not preparation, administration, or dosing instructions.
NAD+ preparations, concentrations and routes vary widely and are not interchangeable; there is no responsible universal vial example.
Important: Vial strength, diluent identity, compatibility, sterility, stability and beyond-use time are product-specific. Never infer them from this arithmetic example. Use manufacturer, pharmacy, study, or licensed-clinician instructions for an actual preparation.
Cycle & Supplies Planning
Phase-by-phase cycle math showing how long a vial lasts and the estimated supplies required.
NAD+ preparations, concentrations and routes vary widely and are not interchangeable; there is no responsible universal vial example.
Planning boundary: These are arithmetic examples based on the displayed research schedule—not personal dosing or purchasing instructions. Confirm product format, compatibility, route, sterility, storage, and discard timing independently. U-100 units measure liquid volume, not potency.
Safety signal
Safety depends on route, formulation and exposure. Cellular importance alone does not prove clinical benefit.
Reported doses describe either a specific study or an unverified community pattern. Neither is personal medical guidance.